Alnabulsi, Ayham

Blihoghe, Daniela

Brown, Gordon T

Cash, Beatriz Giminez

Johansson, Petronella

Murray, Graeme I

PLoS ONE

English

PubMed

<div>Colorectal cancer is one of the most common types of cancer with over fifty percent of patients presenting at an advanced stage. Retinoic acid is a metabolite of vitamin A and is essential for normal cell growth and aberrant retinoic acid metabolism is implicated in tumourigenesis. This study has profiled the expression of retinoic acid metabolising enzymes using a well characterised colorectal cancer tissue microarray containing 650 primary colorectal cancers, 285 lymph node metastasis and 50 normal colonic mucosal samples. Immunohistochemistry was performed on the tissue microarray using monoclonal antibodies which we have developed to the retinoic acid metabolising enzymes CYP26A1, CYP26B1, CYP26C1 and lecithin retinol acyl transferase (LRAT) using a semi-quantitative scoring scheme to assess expression. Moderate or strong expression of CYP26A1was observed in 32.5% of cancers compared to 10% of normal colonic epithelium samples (p<0.001). CYP26B1 was moderately or strongly expressed in 25.2% of tumours and was significantly less expressed in normal colonic epithelium (p<0.001). CYP26C1 was not expressed in any sample. LRAT also showed significantly increased expression in primary colorectal cancers compared with normal colonic epithelium (p<0.001). Strong CYP26B1 expression was significantly associated with poor prognosis (HR = 1.239, 95%CI = 1.104–1.390, χ2 = 15.063, p = 0.002). Strong LRAT was also associated with poorer outcome (HR = 1.321, 95%CI = 1.034–1.688, χ2 = 5.039, p = 0.025). In mismatch repair proficient tumours strong CYP26B1 (HR = 1.330, 95%CI = 1.173–1.509, χ2 = 21.493, p<0.001) and strong LRAT (HR = 1.464, 95%CI = 1.110–1.930, χ2 = 7.425, p = 0.006) were also associated with poorer prognosis. This study has shown that the retinoic acid metabolising enzymes CYP26A1, CYP26B1 and LRAT are significantly overexpressed in colorectal cancer and that CYP26B1 and LRAT are significantly associated with prognosis both in the total cohort and in those tumours which are mismatch repair proficient. CYP26B1 was independently prognostic in a multivariate model both in the whole patient cohort (HR = 1.177, 95%CI = 1.020–1.216, p = 0.026) and in mismatch repair proficient tumours (HR = 1.255, 95%CI = 1.073–1.467, p = 0.004).</div

Gordon T. Brown (532127)

Beatriz Gimenez Cash (532128)

Daniela Blihoghe (472704)

Petronella Johansson (532129)

Ayham Alnabulsi (532130)

Graeme I. Murray (195455)

The Francis Crick Institute

The Expression and Prognostic Significance of Retinoic Acid Metabolising Enzymes in Colorectal Cancer

The Open University

Abiraterone in prostate cancer: A new angle to an old problem.

Advances in human cytochrome p450 and personalized medicine.

Antibodies as a probe in cytochrome P450 research.

Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder.

Arachidonic acid cytochrome P450 epoxygenase pathway.

Aromatase inhibitors in the treatment of breast cancer.

Biomarker use in colorectal cancer therapy.

Biomarkers for colorectal cancer: Identification through proteomics. Current Proteomics 7: 212–221.

Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins.

Colorectal cancer chemoprevention: the potential of a selective approach. Expert Rev Anticancer Ther 10: 1559–1562. CYP26 and Colorectal Cancer

Colorectal cancer molecular biology moves into clinical practice.

Colorectal cancer.

Comparison of the function and expression of CYP26A1 and CYP26B1, the two retinoic acid hydroxylases.

Current and emerging concepts in tumour metastasis.

CYP epoxygenase derived EETs: From cardiovascular protection to human cancer therapy.

Cytochrome P450 CYP3A in human renal cell cancer.

Cytochrome P450 profile of colorectal cancer: Identification of markers of prognosis.

Cytochrome P450 regulation: The interplay between its heme and apoprotein moieties in synthesis, assembly, repair, and disposal.

Cytochrome p450 retinoic acid 4-hydroxylase inhibitors: Potential agents for cancer therapy.

Cytochrome P450-activated prodrugs: Targeted drug delivery.

Cytochrome P450-dependent eicosanoid production and crosstalk.

Cytochrome P450-dependent metabolism of omega-6 and omega-3 long-chain polyunsaturated fatty acids.

Cytochrome P450-derived eicosanoids: The neglected pathway in cancer.

Cytochrome P450s in the regulation of cellular retinoic acid metabolism.

Dataset for colorectal cancer (2nd edition). The Royal College of Pathologists:

Design and synthesis of substituted imidazole and triazole N-phenylbenzo[d]oxazolamine inhibitors of retinoic acid metabolizing enzyme CYP26.

Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma.

Epigenetic biomarkers in colorectal cancer diagnostics.

Epigenetics of colorectal cancer.

Expression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase.

Expression of cytochrome P450IA in breast cancer.

Expression of the retinoic acid-metabolizing enzyme CYP26A1 limits programmed cell death.

Focus on molecules: Lecithin retinol acyltransferase.

Functional properties and substrate characterization of human CYP26A1, CYP26B1, and CYP26C1 expressed by recombinant baculovirus in insect cells.

Goel A

Hepatic vitamin A preloading reduces colorectal cancer metastatic multiplicity in a mouse xenograft model.

Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer.

Inhibition of P450 17 as a new strategy for the treatment of prostate cancer.

Lecithin:Retinol acyltransferase is critical for cellular uptake of vitamin A from serum retinolbinding protein.

Matrix metalloproteinases and their inhibitors in gastric cancer.

Microsatellite instability and colorectal cancer.

Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment.

Molecular genetics of colorectal cancer.

Monoclonal antibodies and multifunctional cytochrome P450: Drug metabolism as paradigm.

Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: Potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells.

Novel prognostic biomarkers in colorectal cancer.

Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1Himidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold.

Orphans in the human cytochrome P450 superfamily: Approaches to discovering functions and relevance in pharmacology.

Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors.

Overview of retinoid metabolism and function.

Predictive and prognostic markers in colorectal cancer.

Predictive molecular classifiers in colorectal cancer.

Profiling markers of prognosis in colorectal cancer.

Profiling the expression of cytochrome P450 in breast cancer.

Prognostic and predictive markers in stage II colon cancer: Is there a role for gene expression profiling?

Progress in the identification of plasma biomarkers of colorectal cancer.

Reduced lecithin: Retinol acyltransferase expression correlates with increased pathologic tumor stage in bladder cancer.

Reduced lecithin:retinol acyltransferase expression in human breast cancer.

Regulation of cytochrome P450 by posttranslational modification.

Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1.

Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens.

Stereoselectivity of human cytochrome p450 in metabolic and inhibitory activities.

Structural diversity of cytochrome P450 enzyme system.

Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates.

The expression of CYP2W1: A prognostic marker in colon cancer.

The expression of cytochrome P-450, epoxide hydrolase, and glutathione Stransferase in hepatocellular carcinoma.

The expression profile of RNA-binding proteins in primary and metastatic colorectal cancer: Relationship of heterogeneous nuclear ribonucleoproteins with prognosis.

The monooxygenase, peroxidase, and peroxygenase properties of cytochrome P450.

The proteomics of colorectal cancer: Identification of a protein signature associated with prognosis.

The role of CYP26 enzymes in retinoic acid clearance.

The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis.

Tumor-specific expression of cytochrome P450 CYP1B1.

Tumour cytochrome P450 and drug activation.

Tumour-specific expression of CYP2W1: Its potential as a drug target in cancer therapy.

The expression and prognostic significance of retinoic acid metabolising enzymes in colorectal cancer

Gordon T. Brown

Beatriz Gimenez Cash

Daniela Blihoghe

Petronella Johansson

Ayham Alnabulsi

Graeme I. Murray

Crossref

Colorectal cancer is one of the most common types of cancer with over fifty percent of patients presenting at an advanced stage. Retinoic acid is a metabolite of vitamin A and is essential for normal cell growth and aberrant retinoic acid metabolism is implicated in tumourigenesis. This study has profiled the expression of retinoic acid metabolising enzymes using a well characterised colorectal cancer tissue microarray containing 650 primary colorectal cancers, 285 lymph node metastasis and 50 normal colonic mucosal samples. Immunohistochemistry was performed on the tissue microarray using monoclonal antibodies which we have developed to the retinoic acid metabolising enzymes CYP26A1, CYP26B1, CYP26C1 and lecithin retinol acyl transferase (LRAT) using a semi-quantitative scoring scheme to assess expression. Moderate or strong expression of CYP26A1was observed in 32.5% of cancers compared to 10% of normal colonic epithelium samples (p<0.001). CYP26B1 was moderately or strongly expressed in 25.2% of tumours and was significantly less expressed in normal colonic epithelium (p<0.001). CYP26C1 was not expressed in any sample. LRAT also showed significantly increased expression in primary colorectal cancers compared with normal colonic epithelium (p<0.001). Strong CYP26B1 expression was significantly associated with poor prognosis (HR = 1.239, 95%CI = 1.104-1.390, χ(2) = 15.063, p = 0.002). Strong LRAT was also associated with poorer outcome (HR = 1.321, 95%CI = 1.034-1.688, χ(2) = 5.039, p = 0.025). In mismatch repair proficient tumours strong CYP26B1 (HR = 1.330, 95%CI = 1.173-1.509, χ(2)= 21.493, p<0.001) and strong LRAT (HR = 1.464, 95%CI = 1.110-1.930, χ(2) = 7.425, p = 0.006) were also associated with poorer prognosis. This study has shown that the retinoic acid metabolising enzymes CYP26A1, CYP26B1 and LRAT are significantly overexpressed in colorectal cancer and that CYP26B1 and LRAT are significantly associated with prognosis both in the total cohort and in those tumours which are mismatch repair proficient. CYP26B1 was independently prognostic in a multivariate model both in the whole patient cohort (HR = 1.177, 95%CI = 1.020-1.216, p = 0.026) and in mismatch repair proficient tumours (HR = 1.255, 95%CI = 1.073-1.467, p = 0.004)

Gordon T Brown

Graeme I Murray

Directory of Open Access Journals

The expression and prognostic significance of retinoic acid metabolising enzymes in colorectal cancer.

The expression and prognostic significance of retinoic acid metabolising enzymes in colorectal cancer

Abstract

Similar works

Full text

Available Versions

The Francis Crick Institute

The Open University

Crossref

Directory of Open Access Journals